- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04480567
AAV Gene Therapy Study for Subjects With PKU
October 6, 2021 updated by: BioMarin Pharmaceutical
A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects With Phenylketonuria
This is a Phase 1/2, open-label, dose escalation study to evaluate the safety, efficacy and tolerability of BMN 307 in adult PKU subjects with PAH deficiency.
Participants will receive a single administration of BMN 307 and will be followed for safety and efficacy.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Birmingham, United Kingdom, B15 2TH
- University Hospital Birmingham NHS Foundation Trust
-
-
-
-
Florida
-
Tampa, Florida, United States, 33606
- University of South Florida
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Morristown Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center - Houston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects with diagnosis of PKU which is a condition characterized by PAH deficiency
- Ability and willingness to maintain dietary protein intake consistent with baseline intake
- Willingness to abstain from hepatotoxic substances post-BMN 307 administration
- Willingness and capable per investigator opinion to comply with study procedures and requirements
- Willingness to use effective methods of contraception
- Plasma Phe levels > 600 µmol/L
Exclusion Criteria:
- Subjects with primary BH4 deficiency or other forms of BH4 metabolism deficiency
- Clinically significant liver dysfunction or disease
- Prior treatment with gene therapy
- Any condition that, in the opinion of the investigator or Sponsor, would prevent the subject from fully complying with the requirements of the study
- History of malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose 1 of BMN 307
|
AAV Gene Therapy Infusion
|
Experimental: Dose 2 of BMN 307
|
AAV Gene Therapy Infusion
|
Experimental: Dose 3 of BMN 307
|
AAV Gene Therapy Infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in mean Plasma Phe levels
Time Frame: baseline, week 12
|
baseline, week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in mean Plasma Phe levels
Time Frame: baseline, week 96
|
baseline, week 96
|
Change from baseline in dietary protein intake from intact food
Time Frame: baseline, week 96
|
baseline, week 96
|
Number of participants with treatment-emergent adverse event
Time Frame: At 5 years
|
At 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 24, 2020
Primary Completion (Anticipated)
December 1, 2027
Study Completion (Anticipated)
December 1, 2027
Study Registration Dates
First Submitted
July 8, 2020
First Submitted That Met QC Criteria
July 20, 2020
First Posted (Actual)
July 21, 2020
Study Record Updates
Last Update Posted (Actual)
October 7, 2021
Last Update Submitted That Met QC Criteria
October 6, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 307-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phenylketonuria (PKU)
-
BioMarin PharmaceuticalRecruitingPhenylketonuria (PKU)United States
-
University of Southern CaliforniaBioMarin PharmaceuticalCompleted
-
Stanford UniversityBioMarin PharmaceuticalWithdrawnClassical Phenylketonuria(PKU)
-
BioMarin PharmaceuticalRecruitingPhenylketonuria (PKU)United States, Germany, Italy
-
Nutricia ResearchCompleted
-
BioMarin PharmaceuticalCompletedPhenylketonuria (PKU)United States, Turkey, Canada, France, Germany, Italy, United Kingdom
-
BioMarin PharmaceuticalActive, not recruitingPhenylketonuria (PKU)United States, Germany
-
BioMarin PharmaceuticalCompletedPhenylketonuria (PKU)United States
-
BioMarin PharmaceuticalCompletedPhenylketonuria (PKU)United States
-
University of British ColumbiaRare Disease Foundation, Vancouver, CanadaCompleted
Clinical Trials on BMN 307
-
Suzhou Connect Biopharmaceuticals, Ltd.CompletedModerate to Severe Ulcerative ColitisUnited States, China, Pakistan, Ukraine
-
Suzhou Connect Biopharmaceuticals, Ltd.Tigermed Consulting Co., Ltd; Nucleus Network LtdCompleted
-
Contineum TherapeuticsRecruitingRelapsing Remitting Multiple SclerosisUnited States
-
Hangzhou Jiayin Biotech LtdRecruitingSpinal Muscular Atrophy Type IChina
-
Pipeline Therapeutics, Inc.Completed
-
Suzhou Connect Biopharmaceuticals, Ltd.Completed
-
Pipeline Therapeutics, Inc.Completed
-
BioMarin PharmaceuticalRecruitingHereditary Angioedema | HAEUnited States, Spain, Australia
-
BioMarin PharmaceuticalCompletedPompe DiseaseUnited States, United Kingdom, France, Australia, Germany
-
BioMarin PharmaceuticalTerminatedPompe DiseaseUnited States, United Kingdom, Australia, France, Germany, New Zealand